Lycium ruthenicum extract alleviates high-fat diet-induced nonalcoholic fatty liver disease via enhancing the AMPK signaling pathway

Lin,Jiayao; Zhang,Yu; Wang,Xinqing; Wang,Wenwen

doi:10.3892/mmr.2015.3840

Lycium ruthenicum extract alleviates high-fat diet-induced nonalcoholic fatty liver disease via enhancing the AMPK signaling pathway

Authors:
- Jiayao Lin
- Yu Zhang
- Xinqing Wang
- Wenwen Wang
View Affiliations

Affiliations: Department of Geriatrics, Huashan Hospital, Fudan University, Shanghai 200040, P.R. China
Published online on: May 25, 2015 https://doi.org/10.3892/mmr.2015.3840
Pages: 3835-3840

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Nonalcoholic fatty liver disease (NAFLD) is a common liver disease that currently has no standard treatment. The present study aimed to evaluate the effects of Lycium ruthenicum extract (LRE) on high‑fat diet (HFD)-induced NAFLD, and elucidate the underlying molecular mechanisms. To determine the hepatoprotective effect of LRE, C57BL/6 mice were fed a normal control diet, high‑fat diet (HFD), HFD supplemented with 2 g/kg LRE, or HFD supplemented with 5 g/kg LRE. Treatment with LRE markedly decreased the levels of triglycerides, total cholesterol, aspartate aminotransferase and alanine aminotransferase in the serum of mice fed a HFD, and improved glucose metabolism and insulin sensitivity in NAFLD mice. In addition, treatment with LRE significantly decreased the expression levels of sterol regulatory element‑binding protein 1c and fatty acid synthase, and markedly increased the expression of peroxisome proliferator‑activated receptor α and peroxisome proliferator‑activated receptor γ co‑activator 1α. Furthermore, LRE treatment significantly increased the activation of adenosine monophosphate‑activated protein kinase (AMPK) in the liver. These results suggested that LRE is able to suppress lipid accumulation in HFD‑fed C57BL/6 mice via enhancement of the AMPK pathway.

View Figures

View References

1	Alba L and Lindor K: Review article: Non-alcoholic fatty liver disease. Aliment Pharmacol Ther. 17:977–986. 2003. View Article : Google Scholar : PubMed/NCBI
2	Jaskiewicz K, Rzepko R and Sledzinski Z: Fibrogenesis in fatty liver associated with obesity and diabetes mellitus type 2. Dig Dis Sci. 53:785–788. 2008. View Article : Google Scholar
3	Dong H, Lu FE and Zhao L: Chinese herbal medicine in the treatment of nonalcoholic fatty liver disease. Chin J Integr Med. 18:152–160. 2012. View Article : Google Scholar : PubMed/NCBI
4	Wu PS, Wu SJ, Tsai YH, Lin YH and Chao JC: Hot water extracted Lycium barbarum and Rehmannia glutinosa inhibit liver inflammation and fibrosis in rats. Am J Chin Med. 39:1173–1191. 2011. View Article : Google Scholar : PubMed/NCBI
5	Xiao J, Liong EC, Ching YP, Chang RC, Fung ML, Xu AM, So KF and Tipoe GL: Lycium barbarum polysaccharides protect rat liver from non-alcoholic steatohepatitis-induced injury. Nutr Diabetes. 3:e812013. View Article : Google Scholar : PubMed/NCBI
6	Ni W, Gao T, Wang H, Du Y, Li J, Li C, Wei L and Bi H: Anti-fatigue activity of polysaccharides from the fruits of four Tibetan plateau indigenous medicinal plants. J Ethnopharmacol. 150:529–535. 2013. View Article : Google Scholar : PubMed/NCBI
7	Li J, Li SZ, Feng WJ and Yuan H: In vitro antioxidant and free radical scavenging activities of total flavonoids from the leaves of Lycium ruthenicum Murr. Food Sci. 13:0612010.
8	Peng Q, Song J, LV X, Wang Z, Huang L and Du Y: Structural characterization of an arabinogalactan-protein from the fruits of Lycium ruthenicum. J Agric Food Chem. 60:9424–9429. 2012. View Article : Google Scholar : PubMed/NCBI
9	Wang JH, Chen XQ and Zhang WJ: Study on hypoglycemic function of polysaccharides from Lycium ruthenicum Murr. fruit and its mechanism. Food Sci. 30:244–248. 2009.
10	Guo S, Copps KD, Dong X, Park S, Cheng Z, Pocai A, Rossetti L, Sajan M, Farese RV and White MF: The Irs1 branch of the insulin signaling cascade plays a dominant role in hepatic nutrient homeostasis. Mol Cell Biol. 29:5070–5083. 2009. View Article : Google Scholar : PubMed/NCBI
11	Malaguarnera M, Di Rosa M, Nicoletti F and Malaguarnera L: Molecular mechanisms involved in NAFLD progression. J Mol Med (Berl). 87:679–695. 2009. View Article : Google Scholar
12	Musso G, Gambino R and Cassader M: Recent insights into hepatic lipid metabolism in non-alcoholic fatty liver disease (NAFLD). Prog Lipid Res. 48:1–26. 2009. View Article : Google Scholar
13	Bijland S, Mancini SJ and Salt IP: Role of AMP-activated protein kinase in adipose tissue metabolism and inflammation. Clin Sci. 124:491–507. 2013. View Article : Google Scholar : PubMed/NCBI
14	Cohen JC, Horton JD and Hobbs HH: Human fatty liver disease: Old questions and new insights. Science. 332:1519–1523. 2011. View Article : Google Scholar : PubMed/NCBI
15	Rahimi RS and Landaverde C: Nonalcoholic fatty liver disease and the metabolic syndrome: Clinical implications and treatment. Nutr Clin Pract. 28:40–51. 2013. View Article : Google Scholar : PubMed/NCBI
16	Sanyal AJ, Campbell-Sargent C, Mirshahi F, Rizzo WB, Contos MJ, Sterling RK, Luketic VA, Shiffman ML and Clore JN: Nonalcoholic steatohepatitis: Association of insulin resistance and mitochondrial abnormalities. Gastroenterology. 120:1183–1192. 2001. View Article : Google Scholar : PubMed/NCBI
17	Utzschneider KM and Kahn SE: Review: The role of insulin resistance in nonalcoholic fatty liver disease. J Clin Endocrinol Metab. 91:4753–4761. 2006. View Article : Google Scholar : PubMed/NCBI
18	Serviddio G, Bellanti F and Vendemiale G: Free radical biology for medicine: Learning from nonalcoholic fatty liver disease. Free Radic Biol Med. 65:952–968. 2013. View Article : Google Scholar : PubMed/NCBI
19	Shimano H, Yahagi N, Amemiya-Kudo M, Hasty AH, Osuga J, Tamura Y, Shionoiri F, Iizuka Y, Ohashi K, Harada K, Gotoda T, et al: Sterol regulatory element-binding protein-1 as a key transcription factor for nutritional induction of lipogenic enzyme genes. J Biol Chem. 274:35832–35839. 1999. View Article : Google Scholar : PubMed/NCBI
20	Matsumoto M, Ogawa W, Akimoto K, Inoue H, Miyake K, Furukawa K, Hayashi Y, Iguchi H, Matsuki Y, Hiramatsu R, Shimano H, et al: PKClambda in liver mediates insulin-induced SREBP-1c expression and determines both hepatic lipid content and overall insulin sensitivity. J Clin Invest. 112:935–944. 2003. View Article : Google Scholar : PubMed/NCBI
21	Rakhshandehroo M, Knoch B, Müller M and Kersten S: Peroxisome proliferator-activated receptor alpha target genes. PPAR Res. 2010:6120892010. View Article : Google Scholar : PubMed/NCBI
22	Reddy JK and Rao MS: Lipid metabolism and liver inflammation. II Fatty liver disease and fatty acid oxidation. Am J Physiol Gastrointest Liver Physiol. 290:G852–G858. 2006. View Article : Google Scholar : PubMed/NCBI
23	Cao H, Maeda K, Gorgun CZ, Kim HJ, Park SY, Shulman GI, Kim JK and Hotamisligil GS: Regulation of metabolic responses by adipocyte/macrophage fatty acid-binding proteins in leptin-deficient mice. Diabetes. 55:1915–1922. 2006. View Article : Google Scholar : PubMed/NCBI
24	Ahmed MH and Byrne CD: Modulation of sterol regulatory element binding proteins (SREBPs) as potential treatments for non-alcoholic fatty liver disease (NAFLD). Drug Discov Today. 12:740–747. 2007. View Article : Google Scholar : PubMed/NCBI
25	Kohjima M, Higuchi N, Kato M, Kotoh K, Yoshimoto T, Fujino T, Yada M, Yada R, Harada N, Enjoji M, Takayanagi R and Nakamuta M: SREBP-1c, regulated by the insulin and AMPK signaling pathways, plays a role in nonalcoholic fatty liver disease. Int J Mol Med. 21:507–511. 2008.PubMed/NCBI
26	Barroso E, Rodriguez-Calvo R, Serrano-Marco L, Astudillo AM, Balsinde J, Palomer X and Vasquez-Carrera M: The PPARβ/δ activator GW501516 prevents the down-regulation of AMPK caused by high-fat diet in liver and amplifies the PGC-1α-lipin 1-PPARα pathway leading to increased fatty acid oxidation. Endocrinology. 152:1848–1859. 2011. View Article : Google Scholar : PubMed/NCBI
27	Viollet B, Athea Y, Mounier R, Guigas B, Zarrinpashneh E, Horman S, Lantier L, Hebrard S, Devin-Leclerc J, Beauloye C, Foretz M, et al: AMPK: Lessons from transgenic and knockout animals. Front Biosci (Landmark Ed). 14:19–44. 2009. View Article : Google Scholar
28	Li Y, Xu S, Mihaylova MM, Zheng B, Hou X, Jiang B, Park O, Luo Z, Lefai E, Shyy JY, Gao B, et al: AMPK phosphorylates and inhibits SREBP activity to attenuate hepatic steatosis and atherosclerosis in diet-induced insulin-resistant mice. Cell Metab. 13:376–388. 2011. View Article : Google Scholar : PubMed/NCBI